ProCE Banner Activity


Optimizing Integration of Precision Therapy Into the Treatment of HER2-Low, HR-Positive, and Triple Negative Breast Cancer: A Focus on HER2 Targeted and TROP-2–Targeted Therapy


Watch this on-demand webcast from a June 2023 symposium featuring Sara Hurvitz, MD, FACP; Aditya Bardia, MD, MPH; and Shanu Modi, MD, on integrating recent approvals, emerging clinical data, and treatment-related adverse event management into clinical practice for the treatment of HER2-low, HR-positive, and triple-negative breast cancer.

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: June 20, 2023

Expiration: June 19, 2024

No longer available for credit.



Aditya Bardia

Aditya Bardia, MD, MPH, FASCO

Professor of Medicine
Geffen School of Medicine at UCLA
Director, Breast Oncology Program
Assistant Chief (Translational Research)
Division of Medical Oncology
Director of Translational Research Integration
UCLA Health Jonsson Comprehensive Cancer Center
Los Angeles, California

Sara A. Hurvitz

Sara A. Hurvitz, MD, FACP

Professor of Medicine
Head, Division of Hematology and Oncology
Department of Medicine, UW Medicine
Senior Vice President
Clinical Research Division
Fred Hutchinson Cancer Center
Seattle, Washington

Shanu Modi

Shanu Modi, MD

Professor of Medicine
Section Head, HER2 Breast Program
Breast Medicine Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
Weill Cornell Medical College
New York, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences Inc.


Daiichi Sankyo

Gilead Sciences, Inc.

Target Audience

This program is intended for medical oncologists, pathologists, and other healthcare professionals caring for patients with breast cancer.

Program Learning Goal

This program aims to improve learners’ knowledge, confidence, and competence in integrating recent approvals, emerging clinical data, and treatment-related adverse event management into clinical practice for the treatment of HER2-low, HR-positive, and triple-negative breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Plan therapeutic strategies for patients with HER2-low metastatic breast cancer based on the available clinical data and expert recommendations

  • Implement new expert and guideline-recommended testing and assessment of HER2 expression to expand HER2-targeted treatment options to patients who previously would be classified as HER2 negative

  • Develop a treatment plan with agents targeting TROP-2 in patients with TNBC or endocrine-resistant HR-positive/HER2-negative metastatic breast cancer

  • Distinguish current indications, efficacy, and toxicity profiles among available and investigational agents targeting TROP-2 in metastatic breast cancer

  • Construct a supportive care plan for patients experiencing treatment-related symptoms while receiving a HER2- or TROP-2–targeted therapy


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Sara Hurvitz, MD, FACP: researcher: Ambrx, Amgen, Arvinas, AstraZeneca, Bayer, CytomX, Daiichi Sankyo, Dantari, Dignitana, Genentech/Roche, G1 Therapeutics, Gilead, GlaxoSmithKline, Greenwich Life Sciences, Immunomedics, Lilly, Macrogenics, Novartis, OBI Pharma, Orinove, Orum, Pfizer, Phoenix Molecular Designs, Pieris, PUMA, Radius, Samumed, Sanofi, Seattle Genetics/Seagen, Zymeworks. 

Aditya Bardia, MD, MPH: consultant/advisor: Daiichi Sankyo/AstraZeneca, Foundation Medicine, Genentech, Immunomedics/Gilead, Lilly, Merck, Novartis, Pfizer, Phillips, Radius Health, Sanofi; researcher (paid to institution): Daiichi Sankyo/AstraZeneca, Genentech, Immunomedics/Gilead, Lilly, Merck, Novartis, Pfizer, Radius Health, Sanofi. 

Shanu Modi, MD: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, Genentech, Gilead, Seattle Genetics; researcher: AstraZeneca, Daiichi Sankyo, Genentech, Seattle Genetics. 

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from June 20, 2023, through June 19, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


The program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement

Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.